Top Markets
#1 Akedo Akedo +60.74%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.99%
#4 Velvet Velvet +41.65%
#5 Black Phoenix Black Phoenix +34.54%
#6 τemplar τemplar +26.67%
#7 Ribbita by Virtuals Ribbita by Virtuals +18.82%
#8 Bitway Bitway +17.84%
#9 Perle Perle +15.44%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +15.42%
Coin of the day
Akedo Akedo
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
CohBar, Inc. CohBar, Inc.

CohBar, Inc.

CWBR
Classificação em ações #38304
CohBar Inc. is a clinical-stage biotechnology company dedicated to the... CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.
Preço da ação
$0.41
Última sincronização: 2025-01-23
Valor de mercado
$1.08M
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar CohBar, Inc. (CWBR)

Categoria

Healthcare
Receita da CohBar, Inc. (CWBR)
Receita em Jun 2023 TTM: 0.00
De acordo com os últimos relatórios financeiros da CohBar, Inc., a receita atual da empresa (TTM) é 0.00. Em 2021, a empresa obteve uma receita de 0.00 igual a a receita do ano 2020, que foi de 0.00. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da CohBar, Inc. de 2012 a 2026
Receita no final de cada ano
Ano Receita Alterar
2026 (TTM) 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
2015 0.00 0.00%
2014 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE